Navigation Links
Neurobiological Technologies Announces Filing of Certificate of Dissolution and Closing of Stock Transfer Books
Date:12/17/2009

EMERYVILLE, Calif., Dec. 17 /PRNewswire/ -- Neurobiological Technologies, Inc. (formerly NTII) ("NTI") announced today that it filed a Certificate of Dissolution with the Secretary of State of the State of Delaware on December 17, 2009. Certificates of Dissolution generally become effective upon filing. The Certificate of Dissolution provides for the dissolution of NTI under the Delaware General Corporation Law. In connection with the filing of its Certificate of Dissolution, NTI also closed its stock transfer books to coincide with the voluntary delisting of its securities from the Nasdaq Capital Market, effective prior to the opening of business on December 17, 2009.

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc. is a biopharmaceutical company historically focused on developing investigational drugs for central nervous system conditions.

SOURCE Neurobiological Technologies, Inc.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Neurobiological Technologies Announces Extraordinary Dividend of $0.18 per Share
2. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
3. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
4. Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futility Analysis
5. Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
6. Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
7. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
8. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
9. Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimers Disease
10. Wound Management Technologies, Inc. Targets Multi-Billion Dollar Biomaterials Market; Releases Update on Resorbable Orthopedics
11. AVAX Technologies, Inc. Closes Bridge Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2017)... -- Sapheneia and Scannerside received FDA 510(k) clearance to ... third-party Vendor neutral CT product that makes it affordable ... current MITA standards. ... specifically designed to provide CT operators, prior to a ... a predefined threshold. Scannerside Dose Check is intended to ...
(Date:9/5/2017)... Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ORMP) ... the development of oral drug delivery systems, announced today ... U.S. Food and Drug Administration (FDA) regarding ORMD-0801, the ... At the meeting, the FDA gave clear ... would be a Biologics License Application (BLA).  Such a ...
(Date:8/31/2017)... -- PM360,s annual Innovations Issue, published in December, ... happening across the industry. Established six years ago, this ... a comprehensive look at the newest and most exciting ... companies, startups, divisions, products, services, and strategies from the ... in this industry wants to do better—in all facets ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... Reflections Recovery ... now accredited by The Joint Commission for chemical dependency and behavioral health services. ... U.S. health care organizations that meet the commission’s rigorous standards. Accreditation by The ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... Clinical Plus Coating System for clients that rely on safety and cleanliness. This ... of microorganisms. , Silver has been used for centuries for its antimicrobial properties. ...
(Date:9/20/2017)... ... 2017 , ... Renal Support Network’s annual essay contest celebrates ... The theme “Describe a positive decision that you have made about your healthcare” ... one qualification— to have been diagnosed with chronic kidney disease. This year the ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... medical device compliance and commercialization, has just released a new white paper ... is more adamant than ever about medical device, pharmaceutical, and combination product ...
(Date:9/20/2017)... ... September 20, 2017 , ... Demand generation pioneer ... East-coast edition of MarTech: The Marketing Tech Conference October 2–4, at the Hynes ... 40 speakers — representing such thought-leading companies as JP Morgan Chase, GE ...
Breaking Medicine News(10 mins):